On July 21, 2026, the U.S. Court of Appeals for the D.C. Circuit delivered a pivotal ruling in Novartis Pharmaceuticals Corp. v. Robert F. Kennedy Jr., Secretary of Health and Human Services — a consolidated challenge by Novartis, Johnson & Johnson, Eli Lilly, and Bristol Myers Squibb (Nos. 25-5177 et al.). The appellate court held that pharmaceutical manufacturers cannot unilaterally replace upfront 340B statutory ceiling price discounts with post-purchase rebate models without express authorization from the HHS Secretary (though the panel also confirmed that a rebate mechanism is permissible in principle if the Secretary designs and authorizes it). Writing for the court, the panel emphasized that federal drug pricing statutes place "the Secretary, not the manufacturers, in the driver's seat" regarding 340B administrative mechanics.
The ruling triggered a rapid regulatory and legislative chain reaction. Within ten days, HHS published a Federal Register notice (August 3, 2026, Document 2026-15633) outlining a revised agency-administered 340B Rebate Model Pilot Program for selected Medicare-negotiated drugs. Two days later (August 5, 2026), a bipartisan group of U.S. Senators introduced the SUSTAIN 340B Act to codify contract pharmacy access, restrict unilateral rebate models, and establish a national 340B data clearinghouse.
This analysis evaluates the legal foundation of the D.C. Circuit opinion, HHS's revised pilot framework, the statutory mechanics of the SUSTAIN 340B Act, and the financial implications across a 340B outpatient drug market that reached $100 billion in CY2025 purchases.
Direct Answer & Key Takeaways
Direct Answer: The July 21, 2026 D.C. Circuit ruling (Novartis v. RFK Jr.) established that drug manufacturers lack legal authority under Section 340B of the Public Health Service Act to mandate rebate models in place of upfront ceiling price discounts without HHS approval. HHS immediately asserted its administrative authority by publishing a Federal Register notice on August 3, 2026 (Doc. 2026-15633) establishing an agency-controlled 340B Rebate Model Pilot Program targeted at Inflation Reduction Act (IRA) Maximum Fair Price (MFP) overlap drugs. Simultaneously, Congress launched the bipartisan SUSTAIN 340B Act (August 5, 2026), creating a legislative blueprint to standardize contract pharmacy dispensing and prevent unilateral manufacturer discount restrictions across the $100 billion program.
+-------------------------------------------------------------------------------------------------------+
| JULY - AUGUST 2026 340B POLICY TRILOGY |
+-------------------+---------------------+-------------------------+-----------------------------------+
| Policy Action | Date / Citation | Issuing Body | Core Legal & Operational Impact |
+-------------------+---------------------+-------------------------+-----------------------------------+
| D.C. Circuit | July 21, 2026 | U.S. Court of Appeals | Strikes down unilateral |
| Court Ruling | Novartis v. RFK Jr. | (D.C. Circuit) | manufacturer rebate conversion; |
| | | | puts HHS in administrative control|
+-------------------+---------------------+-------------------------+-----------------------------------+
| HHS Revised Pilot | August 3, 2026 | Department of Health & | Creates agency-run rebate pilot; |
| Notice | Fed. Reg. 2026-15633| Human Services (HRSA) | targets IRA Maximum Fair Price |
| | | | (MFP) non-duplication overlap |
+-------------------+---------------------+-------------------------+-----------------------------------+
| SUSTAIN 340B | August 5, 2026 | Bipartisan Senate Group | Comprehensive legislative reform; |
| Legislation | Senate Working Group| (Baldwin, Moran, et al.)| codifies contract pharmacy, |
| | | | establishes national clearinghouse|
+-------------------+---------------------+-------------------------+-----------------------------------+
What Exactly Did the July 21, 2026 D.C. Circuit Ruling Decide?
The legal conflict over 340B rebate models arose when major pharmaceutical manufacturers attempted to transition safety-net hospitals and federally qualified health centers (FQHCs) from traditional upfront point-of-sale ceiling price discounts to post-dispensing rebate models. Under manufacturer-designed rebate proposals, covered entities would purchase drugs at full commercial wholesale acquisition cost (WAC) and submit post-dispensing claims data to a third-party platform (such as Kalderos or 340B ESP) to receive a rebate equal to the 340B discount difference within 30 to 60 days.
TRADITIONAL POINT-OF-SALE DISCOUNT (PRESERVED BY COURT)
+------------------+ Order at 340B Ceiling Price +------------------+
| Covered Entity | <------------------------------------------ | Wholesaler / |
| (Hospital/FQHC) | ------------------------------------------ >| Manufacturer |
+------------------+ Pays 340B Discount Price Upfront +------------------+
--------------------------------------------------------------------------------------
UNILATERAL MANUFACTURER REBATE MODEL (INVALIDATED BY D.C. CIRCUIT)
+------------------+ 1. Pays Full Commercial WAC Price +------------------+
| Covered Entity | ------------------------------------------ >| Wholesaler / |
| (Hospital/FQHC) | <------------------------------------------ | Manufacturer |
+------------------+ 2. Ships Commercial Product +------------------+
|
| 3. Submits Claims Data to Third-Party Platform
v
+------------------+ 4. Rebate Paid 30-60 Days Later
| Third-Party Data | ------------------------------------------ > [Rebate Check]
| Platform |
+------------------+
Statutory Language and Judicial Reasoning
In Novartis Pharmaceuticals Corp. v. Robert F. Kennedy Jr., Novartis challenged HRSA enforcement letters that declared unilateral rebate models unlawful under Section 340B(a)(1) of the Public Health Service Act (42 U.S.C. § 256b(a)(1)). The statutory provision mandates that manufacturers "shall... offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price."
The D.C. Circuit panel rejected Novartis’s argument that a post-purchase rebate constitutes an "offer to purchase at or below ceiling price":
- Unilateral Alteration of Statutory Terms: The court held that forcing covered entities to float full commercial capital while awaiting manufacturer approval of post-hoc rebate claims imposes financial and administrative burdens not authorized by Congress.
- Administrative Primacy of HHS: The opinion explicitly established that while HHS may design administrative mechanisms to prevent duplicate discounting under Medicaid or Medicare, individual pharmaceutical sponsors cannot independently erect rebate barriers. The court observed that the manufacturers' reading would "counterintuitively let manufacturers, rather than the Secretary, take the lead in administering the 340B Program, rendering the Secretary's role largely reactive." (Notably, the panel did not hold rebates unlawful per se — it held that any rebate mechanism must be one the Secretary puts in place, not one manufacturers impose on their own.)
- Relationship to Novartis v. Johnson (May 2024): The court distinguished this ruling from its May 2024 decision in Novartis v. Johnson, which had recognized certain manufacturer restrictions on contract pharmacy locations. While the 2024 ruling focused on where drugs could be delivered under statutory "offer" language, the 2026 ruling addresses how pricing is calculated and settled at point of sale, prohibiting unilateral financial restructuring.
Comparative Analysis of Federal Circuit Jurisprudence on 340B
To understand the legal trajectory of 340B litigation leading up to the July 2026 D.C. Circuit ruling, it is necessary to compare how different federal appellate circuits have interpreted Section 340B requirements.
+------------------------------------------------------------------------------------------------------+
| FEDERAL APPELLATE JURISPRUDENCE COMPARISON |
+-------------------+----------------------+--------------------------+--------------------------------+
| Appellate Court | Case Citation | Primary Ruling Topic | Core Legal Holding |
+-------------------+----------------------+--------------------------+--------------------------------+
| D.C. Circuit | Novartis v. RFK Jr. | Unilateral Manufacturer | Invalidates unilateral rebate |
| (July 2026) | (No. 25-5177) | Rebate Models | models; HHS holds sole authority|
+-------------------+----------------------+--------------------------+--------------------------------+
| D.C. Circuit | Novartis v. Johnson | Contract Pharmacy | Permits reasonable condition |
| (May 2024) | (No. 21-5299) | Location Restrictions | on delivery site numbers |
+-------------------+----------------------+--------------------------+--------------------------------+
| 3rd Circuit | Sanofi v. HHS | Contract Pharmacy | Manufacturers not required to |
| (Jan 2023) | (Nos. 21-3167, -3168)| Unlimited Distribution | supply unlimited pharmacies |
+-------------------+----------------------+--------------------------+--------------------------------+
| 8th Circuit | PhRMA v. McClain | State Contract Pharmacy | Upholds state laws protecting |
| (March 2024) | (No. 22-3675) | Protection Mandates | contract pharmacy access |
+-------------------+----------------------+--------------------------+--------------------------------+
Synthesis of Circuit Rulings
The federal courts established a clear legal distinction between distribution conditions and pricing/rebate mechanisms:
- While the 3rd Circuit (Sanofi v. HHS) and D.C. Circuit (Novartis v. Johnson) permitted manufacturers to place reasonable operational limits on the number of contract pharmacy delivery locations, neither court allowed manufacturers to change the financial terms of 340B transactions.
- The July 2026 D.C. Circuit decision draws a hard line: changing an upfront ceiling price discount into a post-sale rebate alters statutory financial terms and requires explicit HHS administrative authorization.
State-Level 340B Protection Laws and Preemption Jurisprudence
While federal courts adjudicated direct disputes between manufacturers and HHS, state legislatures enacted laws protecting safety-net hospitals from manufacturer restrictions.
+------------------------------------------------------------------------------------------------------+
| STATE-LEVEL 340B CONTRACT PHARMACY PROTECTION LAWS |
+-------------------+------------------------+---------------------------------------------------------+
| State / Law | Citation | Key Statutory Protection Provision |
+-------------------+------------------------+---------------------------------------------------------+
| Arkansas | Act 1103 (2021) | Prohibits manufacturers from denying 340B pricing to |
| | Ark. Code § 23-92-604 | any in-state contract pharmacy. (Upheld 8th Cir. in |
| | | PhRMA v. McClain.) |
+-------------------+------------------------+---------------------------------------------------------+
| Louisiana | House Bill 548 (2023) | Bar manufacturers from restricting 340B drug delivery |
| | Act 358 / La. R.S. | to contracted community pharmacies. |
| | § 40:2881 | |
+-------------------+------------------------+---------------------------------------------------------+
| Missouri | Senate Bill 751 (2024) | Imposes $50,000 fine per violation on manufacturers |
| | Mo. Rev. Stat. § 376.414| restricting 340B shipments to contract pharmacies. |
+-------------------+------------------------+---------------------------------------------------------+
In PhRMA v. McClain (8th Cir., March 2024, No. 22-3675), the U.S. Court of Appeals for the Eighth Circuit upheld Arkansas’s Act 1103, ruling that state laws requiring manufacturers to ship 340B drugs to contract pharmacies are not preempted by federal law under either the Food, Drug, and Cosmetic Act (FDCA) or Section 340B itself. (Because that case sided with covered entities rather than manufacturers, it runs in the opposite direction from the Sanofi and Novartis v. Johnson federal enforcement cases above.) This precedent empowered over 20 states to pass similar protection statutes, creating a patchwork of state-level mandates that complicate national biopharmaceutical commercial strategy.
For an operational overview of manufacturer compliance and non-duplication workflows, see our guide on the 340B and IRA MFP non-duplication workflow.
How Does the 340B ADR Panel Resolve Rebate and Ceiling Price Disputes?
An essential component of HHS administrative enforcement is the Administrative Dispute Resolution (ADR) process. Refreshed by HRSA in an April 2024 Final Rule (89 FR 28643, effective June 18, 2024), the ADR process provides a binding administrative venue for resolving overcharge and rebate disputes between covered entities and drug manufacturers.
+------------------------------------------------------------------------------------------------------+
| HRSA 340B ADR DISPUTE RESOLUTION MECHANICS |
+------------------------------------+-----------------------------------------------------------------+
| ADR Operational Feature | Rule Guideline & Administrative Threshold |
+------------------------------------+-----------------------------------------------------------------+
| Monetary Threshold | None. The 2024 Final Rule eliminated the $25,000 minimum that |
| | the 2020 rule had imposed. |
+------------------------------------+-----------------------------------------------------------------+
| ADR Panel Composition | 3-member panel of federal HRSA/HHS subject-matter experts. |
+------------------------------------+-----------------------------------------------------------------+
| Binding Decision Mandate | Panel decisions are final agency decisions binding on parties. |
+------------------------------------+-----------------------------------------------------------------+
| Judicial Appeal Pathway | Appealable to U.S. District Court under Administrative |
| | Procedure Act (APA) arbitrary and capricious standards. |
+------------------------------------+-----------------------------------------------------------------+
A key change in the 2024 ADR regulations was the removal of the $25,000 minimum claim threshold that the 2020 final rule had established — HHS decided not to finalize any monetary floor, so smaller overcharge and rebate claims are now eligible for the panel. The rule also streamlined claim filings by eliminating formal evidentiary court rules.
How Did HHS Respond with a Revised Rebate-Model Pilot and What Does the Federal Register Notice Say?
Recognizing that the court opinion affirmed administrative authority over rebate structures, HHS acted swiftly to establish an agency-governed alternative. On August 3, 2026, HHS and HRSA published a Federal Register notice (Document 2026-15633) establishing the HHS Revised 340B Rebate Model Pilot Program.
+------------------------------------------------------------------------------------------------------+
| HHS REVISED 340B REBATE PILOT PARAMETERS (AUG 2026) |
+-------------------------+----------------------------------------------------------------------------+
| Feature Parameter | HHS Federal Register Guideline (Doc. 2026-15633) |
+-------------------------+----------------------------------------------------------------------------+
| Scope of Eligibility | Restricted to Medicare Inflation Reduction Act (IRA) negotiated drugs |
| | subject to Maximum Fair Price (MFP) non-duplication rules. |
+-------------------------+----------------------------------------------------------------------------+
| Rebate Processing Window| Once a covered entity submits completed claims data, the manufacturer must |
| | pay the rebate (or issue a documented denial) within 10 calendar days. |
+-------------------------+----------------------------------------------------------------------------+
| Submission Window | Covered entities may submit dispense-level claims for up to 45 days after |
| | dispensing; a separate 15-day starting-inventory grace period applies. |
+-------------------------+----------------------------------------------------------------------------+
| Late-Payment Enforcement| No interest penalty. Repeated or systemic noncompliance is handled by |
| | HRSA review and, ultimately, removal of the manufacturer from the Pilot. |
+-------------------------+----------------------------------------------------------------------------+
| Data Platform Oversight | Operated via an HHS-designated, neutral data clearinghouse; manufacturers |
| | cannot mandate proprietary commercial portals. |
+-------------------------+----------------------------------------------------------------------------+
| Dispute Resolution | Binding HRSA Administrative Dispute Resolution (ADR) panel escalation. |
+-------------------------+----------------------------------------------------------------------------+
Key Elements of the HHS Pilot Framework
- Targeted Product Scope: Rather than granting blanket rebate authority across all 340B outpatient drugs, the HHS pilot is strictly bounded to high-cost products subject to both 340B ceiling prices and Medicare Maximum Fair Prices (MFP) under the Inflation Reduction Act. This prevents double-dipping where a manufacturer could be subjected to both a 340B discount and an IRA MFP penalty on the same unit.
- 10-Day Payment Window: To address safety-net hospital cash-flow concerns, the notice requires manufacturers to pay an approved rebate — or issue a documented denial — within 10 calendar days of completed data submission (entities have up to 45 days from dispense to submit). There is no interest penalty; enforcement for repeated noncompliance escalates to HRSA review and removal from the Pilot.
- Neutral Data Clearinghouse: HHS rejected manufacturer-owned data portals, proposing a centralized, neutral data clearinghouse managed under federal contract. Covered entities submit standardized 835/837 EDI claim feeds to verify non-duplication against Medicaid drug rebates and IRA MFP claims.
For background on related Federal Register rulemaking and Medicare price negotiations, examine our report on the IRA Medicare drug negotiation proposed rule 2026.
What Does the Bipartisan SUSTAIN 340B Act Propose?
Two days after the HHS Federal Register notice, a bipartisan coalition of U.S. Senators—led by Sens. Tammy Baldwin (D-WI) and Jerry Moran (R-KS), alongside co-sponsors John Boozman (R-AR), Shelley Moore Capito (R-WV), Tim Kaine (D-VA), and John Hickenlooper (D-CO)—introduced the SUSTAIN 340B Act (Supporting Underserved and Safety-Net Hospitals Through Auditing and Integrity Enforcement).
+---------------------------------------+
| SUSTAIN 340B ACT |
| Bipartisan Senate Bill |
+---------------------------------------+
|
+------------------------------------------+------------------------------------------+
| | |
v v v
+-------------------------+ +-------------------------+ +-------------------------+
| Contract Pharmacy | | Rebate Model | | National 340B |
| Protections | | Statutory Rules | | Clearinghouse |
| Mandates contract | | Prohibits unilateral | | Standardizes 837 data; |
| pharmacy access without | | manufacturer models; | | prevents duplicate |
| geographic limits | | codifies the D.C. | | Medicaid / IRA rebates |
| | | Circuit's holding | | |
+-------------------------+ +-------------------------+ +-------------------------+
Statutory Architecture of the SUSTAIN 340B Act
The SUSTAIN 340B Act creates a statutory compromise designed to end six years of continuous litigation between biopharmaceutical sponsors and safety-net providers:
- Codification of Contract Pharmacy Rights: The bill explicitly amends Section 340B to clarify that manufacturers must permit covered entities to dispense 340B drugs through contract pharmacy arrangements, invalidating single-location restriction policies imposed by over 30 biopharma companies since 2020.
- National 340B Data Clearinghouse: The legislation authorizes $50 million to establish a neutral national data clearinghouse. Covered entities and contract pharmacies submit claim-level data to eliminate duplicate 340B discounts and Medicaid rebates, as well as 340B/IRA MFP overlap.
- Prohibition of Unilateral Rebates: The bill codifies the D.C. Circuit's holding, establishing civil monetary penalties (up to $50,000 per violation) for manufacturers that impose unapproved rebate models or withhold 340B ceiling prices.
- Covered Entity Transparency: To address manufacturer concerns regarding 340B revenue usage, the bill mandates annual reporting by 340B hospitals on net 340B savings and how those funds are reinvested in charity care, uncompensated care, and rural clinic access.
What Changes for Manufacturers, Covered Entities, and Contract Pharmacies?
The convergence of the D.C. Circuit ruling, HHS pilot rulemaking, and the SUSTAIN 340B Act alters commercial and operational strategies across the biopharma ecosystem.
+------------------------------------------------------------------------------------------------------+
| STAKEHOLDER IMPACT MATRIX: 2026 340B REFORM |
+-------------------+-----------------------------------+----------------------------------------------+
| Stakeholder Group | Primary Operational Shift | Financial & Strategic Implications |
+-------------------+-----------------------------------+----------------------------------------------+
| Pharmaceutical | Cannot deploy unilateral rebate | Preserves upfront discount exposure; must |
| Manufacturers | portals; must interface with HHS | integrate with federal clearinghouse and |
| | clearinghouse. | comply with the 10-day pilot payment rule. |
+-------------------+-----------------------------------+----------------------------------------------+
| Safety-Net | Maintains point-of-sale ceiling | Protects hospital working capital; eliminates|
| Hospitals & FQHCs | prices; avoids WAC cash-flow | multi-million dollar rebate float reserves; |
| | strain. | requires reporting on charity care usage. |
+-------------------+-----------------------------------+----------------------------------------------+
| Contract | Restores multi-site contract | Reverses contract pharmacy volume decline; |
| Pharmacies & PBMs | dispensing arrangements under | mandates electronic claim tagging to prevent |
| | SUSTAIN Act. | Medicaid duplicate discount claims. |
+-------------------+-----------------------------------+----------------------------------------------+
Working Capital and Cash-Flow Dynamics
For safety-net health systems operating on thin operating margins (often 1% to 3%), the D.C. Circuit decision prevents a massive working capital drain. Had unilateral manufacturer rebate models been upheld, a large safety-net health system purchasing $100 million annually in 340B outpatient drugs would have been forced to float $30 million to $50 million in commercial WAC capital while awaiting manufacturer rebate adjudications.
For pharmaceutical manufacturers, the ruling requires a pivot away from proprietary data collection portals. Sponsors must focus compliance efforts on participating in HHS ADR panels and integrating data feeds into the proposed national clearinghouse.
How Does This Interact with the $100B CY2025 340B Outpatient-Drug Scale?
Data released by HRSA indicates that 340B covered entities purchased approximately $100 billion in outpatient drugs in CY2025 (measured at 340B ceiling prices). This represents a substantial portion of the U.S. commercial outpatient drug volume.
+------------------------------------------------------------------------------------------------------+
| 340B PROGRAM GROWTH (CY2020 - CY2025, HRSA) |
+-----------------------+-----------------------+--------------------------------------------------------+
| Calendar Year | Total 340B Purchases | Primary Growth Drivers |
+-----------------------+-----------------------+--------------------------------------------------------+
| CY2020 | $38.0 Billion | Specialty biopharma growth |
| CY2022 | $53.7 Billion | Oncology & autoimmune expansion |
| CY2024 | $81.4 Billion | GLP-1 and cell therapy volume |
| CY2025 (HRSA Data) | ~$100.0 Billion | Outpatient clinic expansions (DSH hospitals ~$79.2B) |
+-----------------------+-----------------------+--------------------------------------------------------+
Purchase totals are HRSA covered-entity outpatient-drug purchases measured at 340B ceiling prices. Net program savings are highly methodology-dependent (HRSA, CMS, and academic estimates diverge widely) and are omitted here rather than stated as single figures.
Because 340B volume is heavily weighted toward high-cost specialty categories—including oncology monoclonal antibodies, oral anti-cancer agents, cell therapies, and GLP-1 receptor agonists—the mechanics of how discounts are applied directly impact manufacturer gross-to-net (GTN) reporting and PBM formulary placement.
For related analyses of international and domestic drug pricing policy timelines, see our study on the generic drug tariff onshoring timeline.
Frequently Asked Questions
Can manufacturers still impose a 340B rebate model after the July 2026 ruling?
No. Under the D.C. Circuit ruling in Novartis v. RFK Jr., manufacturers cannot unilaterally replace upfront 340B point-of-sale ceiling price discounts with post-purchase rebate models. Any 340B rebate model must be authorized and administered directly by the HHS Secretary through formal agency rulemaking or approved pilot programs.
What is the HHS revised 340B Rebate Model Pilot Program?
Published in the Federal Register on August 3, 2026 (Doc. 2026-15633), the HHS pilot is an agency-controlled framework designed specifically for Inflation Reduction Act (IRA) Maximum Fair Price (MFP) overlap drugs. It requires manufacturers to pay approved rebates within 10 calendar days of completed claims submission (with no interest penalty; enforcement is HRSA review and removal from the Pilot for repeated noncompliance) and routes data through an independent federal clearinghouse.
Does this ruling affect 340B contract-pharmacy restrictions too?
While the July 2026 D.C. Circuit ruling focused specifically on rebate conversion models, the accompanying bipartisan SUSTAIN 340B Act (introduced August 5, 2026) directly addresses contract pharmacies by creating a statutory mandate requiring manufacturers to honor 340B discounts across contract pharmacy locations.
Sources
- U.S. Court of Appeals for the District of Columbia Circuit: Novartis Pharmaceuticals Corporation v. Robert F. Kennedy Jr., Secretary of Health and Human Services (No. 25-5177, consolidated with Nos. 25-5179, 25-5220, 25-5221, and 25-5236 — a consolidated challenge by Novartis, Johnson & Johnson, Eli Lilly, and Bristol Myers Squibb; Opinion Issued July 21, 2026). https://www.cadc.uscourts.gov/internet/opinions.nsf/
- Federal Register / U.S. Department of Health and Human Services: Notice of Revised 340B Rebate Model Pilot Program for Selected Medicare Negotiated Drugs (Published August 3, 2026, Document 2026-15633). https://www.federalregister.gov/documents/2026/08/03/2026-15633
- Health Resources and Services Administration (HRSA): 340B Drug Pricing Program Annual Outpatient Sales & Covered Entity Data (CY2025 Data Summary). https://www.hrsa.gov/opa
- U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP): Senators Baldwin, Moran, Boozman, Capito, Kaine, and Hickenlooper Introduce the Bipartisan SUSTAIN 340B Act (Press Release & Bill Text, August 5, 2026). https://www.boozman.senate.gov/public/index.cfm/2026/8/senate-340b-bipartisan-working-group-introduces-comprehensive-340b-reform-legislation
- American Hospital Association (AHA): AHA Legal Update on D.C. Circuit 340B Rebate Decision (July 2026 Statement). https://www.aha.org/news/headline/2026-07-21
